Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Inclusion Criteria: * Patient aged ≥55 years old * With newly diagnosed ALL without prior treatment * Capable to receive polychemotherapy (World Health Organization (WHO) performance status ≤2) * With or without meningeal disease * Having signed an Informed Consent Form * Subscribed to social security insurance Exclusion Criteria: * ALL translocation(9;22) and/or BCR-ABL (Breakpoint Cluster Region-Abelson) positive * Performance status incompatible with chemotherapy treatment (WHO score \>2) * Patient presenting with a general or visceral contraindication to intensive treatment including : * Cardiac insufficiency defined as Left Ventricular Ejection Fraction \<50% of the theoretical value * Plasma creatinine concentration 2 times greater than the upper limit of laboratory ranges, except if related to ALL * Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) levels 5 times greater than the upper limit of laboratory ranges, except if related to ALL * Patient with another evolutive cancer other than ALL * Severe evolutive infection, or Human Immunodeficiency Virus (HIV) seropositive or, active hepatitis related to B or C viral infection * Prior treatment with L-asparaginase (irrespective of the form) * History of grade 3 transfusional incident (life threatening) * Patient presenting rare and/or dangerous anti-erythrocyte antibodies thus leading to the unavailability of phenotype compatible Red Blood Cells Concentrate * Patient included in another clinical trial during the last 4 weeks